October 16th, 2026Genetic Analysis Links Insomnia Liability to Higher Inflammation MarkerGenetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.Read more
October 16th, 2026Proinflammatory Diets Linked to Higher MASLD, MetALD MortalityProinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.Read more
October 15th, 2026Autoimmune Hepatitis Regimens Carry Distinct Adverse Event SignalsAn analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.Read more
October 15th, 2026FAQ: How Payers Can Close HIV Prevention and PrEP Access GapsOn National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.Read more
October 15th, 2026Sjögren Disease Extends Beyond Dry Eyes, Dry Mouth: Steven Carsons, MDSjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.Read more
October 14th, 2026MASH Outcomes Hinge on Risk Stratification, Coverage: Zobair Younossi, MDEarly MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.Read more
October 14th, 2026Iberdomide Regimen Cuts RRMM Progression Risk by 51%, Trial FindsThese phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.Read more
October 14th, 2026Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPFAdmilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.Read more